Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"
- Conditions
- Ischemia
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 110
- Registration Number
- NCT00360386
Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 501
- Registration Number
- NCT00359437
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Stilnox Treatment in Elderly Patients With Insomnia
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 115
- Registration Number
- NCT00359229
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
- Conditions
- Depressive Disorder
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2009-04-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 319
- Registration Number
- NCT00358631
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 463
- Registration Number
- NCT00358878
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)
- Conditions
- Smoking Cessation
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 787
- Registration Number
- NCT00358228
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Malvern, Pennsylvania, United States
Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 220
- Registration Number
- NCT00358124
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
- Conditions
- Osteoporosis Postmenopausal
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1231
- Registration Number
- NCT00358176
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford Surrey, United Kingdom
Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
- Conditions
- Smoking
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2008-12-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 602
- Registration Number
- NCT00356967
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
- Conditions
- Head and Neck Neoplasms
- Interventions
- Drug: Concomitant cisplatin, 5-FU and radiotherapyDrug: Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 101
- Registration Number
- NCT00357149
- Locations
- 🇮🇹
Sanofi-Aventis, Milan, Italy